Does NATALIZUMAB Cause Mobility decreased? 1,219 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,219 reports of Mobility decreased have been filed in association with NATALIZUMAB (TYRUKO). This represents 1.9% of all adverse event reports for NATALIZUMAB.
1,219
Reports of Mobility decreased with NATALIZUMAB
1.9%
of all NATALIZUMAB reports
21
Deaths
388
Hospitalizations
How Dangerous Is Mobility decreased From NATALIZUMAB?
Of the 1,219 reports, 21 (1.7%) resulted in death, 388 (31.8%) required hospitalization, and 9 (0.7%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 1,219 reports have been filed with the FAERS database.
What Other Side Effects Does NATALIZUMAB Cause?
Multiple sclerosis relapse (6,478)
Fatigue (4,456)
Multiple sclerosis (4,078)
Memory impairment (3,024)
Malaise (2,523)
Fall (2,481)
Headache (2,476)
Gait disturbance (2,427)
Prescribed underdose (2,162)
Maternal exposure during pregnancy (1,948)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which NATALIZUMAB Alternatives Have Lower Mobility decreased Risk?
NATALIZUMAB vs NATALIZUMAB-SZTN
NATALIZUMAB vs NATAMYCIN
NATALIZUMAB vs NATEGLINIDE
NATALIZUMAB vs NAVITOCLAX
NATALIZUMAB vs NAXITAMAB-GQGK